Serum coenzyme Q10 concentrations in healthy men supplemented with 30 mg or 100 mg coenzyme Q10 for two months in a randomised controlled study

BioFactors

Volumn 18, Issue 1-4, 2003, Pages 185-193

  Zita, Čestmír ^a   Overvad, Kim ^b,c   Mortensen, Svend Aage ^d   Sindberg, Christian Dan ^e   Moesgaard, Sven ^e   Hunter, Douglas A ^e  

^a CHARLES UNIVERSITY   (Czech Republic)

^b AALBORG UNIVERSITY HOSPITAL   (Denmark)

^c AARHUS UNIVERSITY   (Denmark)

^d Mental Health Services CPH   (Denmark)

^e Pharma Nord ApS   (Denmark)

Author keywords

Absorption; Coenzyme Q10; Dose response; Double blind trial; Ubiquinone

Indexed keywords

BIOQUINONE; MYOQINON; PLACEBO; UBIDECARENONE; DRUG DERIVATIVE; UBIQUINONE;

ADULT; AGE DISTRIBUTION; ANTIOXIDANT ACTIVITY; BODY WEIGHT; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; EVALUATION; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SMOKING; STATISTICAL SIGNIFICANCE; AGING; ARTICLE; BLOOD; DOSE RESPONSE; MIDDLE AGED;

ADULT; AGING; BODY WEIGHT; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; HUMANS; MALE; MIDDLE AGED; PLACEBOS; SMOKING; UBIQUINONE;

EID: 0346788999     PISSN: 09516433     EISSN: None     Source Type: Journal    
DOI: 10.1002/biof.5520180221     Document Type: Conference Paper

References (25)

1. L. Ernster and G. Dallner, Biochemical, physiological and medical aspects of ubiquinone function, Biochim et Biophys Acta 1271 (1995), 195-204.
2. 10 in chronic heart failure, angina, and hypertension, Pharmacotherapy 21(7) (2001), 797-806.
3. 10 as a possible treatment for neurodegenerative diseases, Free Rad Res 36(4) (2002), 455-460.
4. 10 preparations in Japan, in: Biomedical and Clinical Aspects of Coenzyme Q, (Vol 4), K. Folkers and Y. Yamamura, eds, Amsterdam: Elsevier Science Publishers B.V., 1984. pp. 132-141.
5. 10, in: Biomedical and Clinical Aspects of Coenzyme Q, (Vol. 6), K. Folkers and Y. Yamamura, eds, Amsterdam: Elsevier Science Publishers B.V., 1991, pp. 215-224.
6. 10 before and after oral supplementation: A bioavailability study, CoQ Res Biol Med 3(1) (1995), 25-32.
7. 10 formulations in healthy volunteers, Molec Aspects Med 15S (1994), s273-280.
8. 10 supplementation on the oxidation resistance of human VLDL+LDL fraction: Absorption and antioxidative properties of oil and granule-based preparations, Free Rad Biol Med 22(7) (1997), 1195-1202.
9. 10 formulations in human subjects, Internat J Vit Nutr Res 68 (1998), 109-113.
10. 10 in healthy subjects, Asia Pac J Clin Nutr 7(1) (1998), 37-40.
11. 10, Asia Pac J Clin Nutr 10(3) (2001), 212-215.
12. 10 preparations, Ann Nutr Metab 47(1) (2003), 16-21.
13. 10 preparations in humans, Int J Clin Pharmacol Ther 41(1) (2003), 42-48.
14. P.O. Edlund, Determination of CoQ, α-tocopherol and cholesterol in biological samples by coupled-column liquid chromatography with coulometric and ultra-violet detection, J Chromatogr 425 (1988), 87-97.
15. 10 in humans, FEBS Letters 443 (1999), 163-166.
16. 10 with 3 months withdrawal period, Molec Aspects Med 15S (1994), s281-285.
17. 10 and d-α-tocopherol in mildly hypercholes-terolemic subjects: A randomized placebo-controlled clinical study, Free Rad Res 33 (2000), 329-340.
18. 10 therapy and exercise duration in stable angina, in: Biomedical and Clinical Aspects of Coenzyme Q, (Vol. 6), K. Folkers and Y. Yamamura, eds, Amsterdam: Elsevier Science Publishers B.V., 1991, pp. 339-348.
19. 10 Association, Frankfurt, Germany, Nov. 2000, pp. 88-89.
20. 10) treatment on glycaemic control, insulin requirement and well-being in patients with Type 1 diabetes mellitus, Diabet Med 16(4) (1999), 312-318
21. 10 treatment in serious heart failure, BioFactors 9(2-4) (1999), 285-289.
22. 10 administration on metabolic control in patients with type 2 diabetes mellitus, BioFactors 9(2-4) (1999), 315-318.
23. 10 in patients with congestive heart failure, Ann Intern Med 132(8) (2000), 636-640.
24. 10 and Ginkgo biloba on warfarin dosage in stable, long-term warfarin treated outpatients. A randomised double-blind, placebo-crossover trial, Thromb Haemost 87 (2002), 1075-1076.
25. 10 and vitamin E on the peroxidation of human low density lipoprotein subfractions, Proc. Natl. Acad. Sci. USA 92 (1995), 9388-9391.